Skip to main content

Search

Clear
Filter by Type
Filter by Topics
Filter by Symptoms & Conditions
Filter by Year
Your Obligation to Provide LEP Services: Four Factors to Consider

Jan 26, 2021/Article

To determine your obligations under Title VI, HHS regulations and guidance, and the Affordable Care Act, consider these four factors.

Did You Rapidly Adopt or Expand Telehealth for COVID-19? Here’s Our Post-Crisis Top 10 ‘To-Do’ List

May 1, 2020/Article

Did you rapidly adopt or expand telehealth in the early weeks of the COVID-19 pandemic? Here's what you should do next.

Final DMEPOS Rule Streamlines Benefit and Payment Processes for Certain Devices

Jan 11, 2022/Review

CMS also chooses to not finalize reforms to the HCPCS Level II application process.

Final 2023 Home Health Rule Turnaround: From Proposed Cut to Slight Increase

Nov 2, 2022/Review

CMS is still implementing cuts, but offsets and a phased-in approach will result in a 0.7% payment increase in 2023.

Coronavirus and Long COVID Update, October 2023

Oct 23, 2023/Roundup

SSRIs and Long COVID, Post-COVID-19 organ abnormalities, lingering symptoms among children, and more.

Directory of Postdoctoral Programs

Feb 12, 2026/Open Access

The postdoctoral programs listed provide opportunities for research and education post academic doctoral degree (ie, PhD) for PTs.

Considerations Related to the PT's Role in Nutrition and Diet

Jun 2, 2020/Article

PTs should consider several factors before engaging in nutrition and diet services.

Responding to Targeted Medical Review

Jul 1, 2017/Column

CMS is reviewing some therapy claims that exceed the $3,700 Medicare Part B threshold. Here's what to know, and what to do, if you are contacted

Understanding Targeted Probe and Educate

Jul 1, 2018/Column

This CMS program is designed to help providers and suppliers reduce claim denials and appeals. Here's what to know if you're contacted.

Blood Flow Restriction, Beyond Just Muscle

Jul 16, 2021/Perspective

Blood flow restriction: it's not just about muscle anymore.